A+ A A-

Download article


Shchupakova A.N., Okulich V.K., Belyaeva L.E., Prudnikov A.R.
Proteolytic activity of neutrophilic elastase as a prognostic factor of cardiovascular diseases development
Educational Establishment «Vitebsk State Order of Peoples’ Friendship Medical University», Vitebsk, Republic of Belarus

Vestnik VGMU. 2016;15(2):17-26.

The review deals with the role of the proteolytic degradation of elastic fibers that make up various tissues and organs under the action of the elastase enzyme. It is the regulator of an inflammation and can act both as a proinflammatory and an anti-inflammatory agent.
The imbalance in the regulation of elastase activity often causes various pathological conditions such as cystic fibrosis, acute respiratory distress syndrome, bronchiectasis, chronic obstructive pulmonary disease, type 2 diabetes mellitus, atherosclerosis, arterial hypertension.
The data of numerous studies proving the importance of determining elastase activity, concentration of elastin-derived peptides (EDPs) and their antibodies for the prognostication of cardiovascular diseases development are given. The level of elastase activity (EDPs and their antibodies) may become with the lapse of time a standard clinical and laboratory parameter, as on the basis of the results of numerous studies it reflects the degree of elastic fibres damage of various organs. The level of elastase activity is one of the indicators, which along with the routine laboratory (low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and others) and clinical (arterial blood pressure, body mass index, age, etc.) data may be of use for the complex assessment of the severity of a patient’s condition at the preclinical stage.
Key words: elastase, elastin, atherosclerosis, arterial hypertension.


1. Bairoch A. The ENZYME database in 2000. Nucleic Acids Res. 2000 Jan;28(1):304-5.
2. Averyanov AV. Rol' neitrofil'noi elastazy v patogeneze khronicheskoi obstruktivnoi bolezni legkikh [Role of neutrophylic elastase in a pathogenesis of a chronic obstructive pulmonary disease]. Tsitokiny i Vospalenie. 2007;6(4):3-8.
3. Bizbiz L, Bonithon-Kopp C, Ducimetieré P, Berr C, Alperovitch A, Robert L. Relation of serum elatase activity to ultrasonographyically assessed carotid artery wall lesions and cardiovascular risk factors. Atherosclerosis. 1996 Feb;120(1-2):47-55.
4. Piwowar A, Knapik-Kordecka M, Warwas M. Concentration of leukocyte elastase in plasma and polymorphouclear neutrophil Extracts in type 2diabetes. Clin Chem Lab Med. 2000 Dec;38(12):1257-61.
5. Nicoloff G, Petkova-Botzova M, Baydanoff S. Serum levels of elastin and collagen-derived peptides in children with high risk of atherosclerosis. Int J Obes. 1995;19(Suppl 2):120.
6. El-Eshmawy MM, El-Adawy EH, Mousa AA, Zeidan AE, El-Baiomy AA, Abdel-Samie ER et al. Elevated serum neutrophil elastase is related to prehypertension and airflow limitation in obese women. BMC Womens Health. 2011 Jan;11:1.
7. Khokha R, Murthy A, Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat Rev Immunol. 2013 Sep;13(9):649-65
8. Kosinets AN, Struchkov YuV. Infektsiia v khirurgii [Infection in surgery]: rukovodstvo. Vitebsk, RB: VGMU; 2004. 512 р.
9. Gettins PG. Serpin structure, mechanism, and function. Chem Rev. 2002 Dec;102(12):4751-804.
10. Hornebeck W, Potazman JP, De Cremoux H, Bellon G, Robert L. Elastase type activity of human serum. Its variation in chronic obstructive lung diseases and atherosclerosis. Clin Physiol Biochem. 1983;1(6):285-92.
11. Sallenave JM, Ryle AP. Purification and characterization of elastase-specific inhibitor. Biol Chem Hoppe Seyler. 1991 Jan;372(1):13-21.
12. Ying QL, Simon SR. Kinetics of the inhibition of human leukocyte elastase by elafin, a 6-kilodalton elastase specific inhibitor from human skin. Biochemistry. 1993 Feb;32(7):1866-74.
13. Wiedow O, Schröder JM, Gregory H, Young JA, Christophers E. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J Biol Chem. 1990 Sep;265(25):14791-5.
14. Wiedow O, Lüademann J, Utecht B. Elafin is a potent inhibitor of proteinase-3. Biochem Biophys Res Commun. 1991 Jan 15;174(1):6-10.
15. Gardiner PJ. Neutrophil elastase inhibitors. Eur Respir Rev. 2002;12:373-4.
16. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med. 1995 Apr;151(4):1075-82.
17. Paczek L, Michalska W, Bartlomiejczyk I. Trypsin, elastase, plasmin and MMP-9 activity in the serum during the human ageing process. Age Ageing. 2008 May;37(3):318-23.
18. Vine N, Powell JT. Metalloproteinases in degenerative aortic disease. Clin Sci (Lond). 1991 Aug;81(2):233-9.
19. Owen CA, Campbell EJ. The cell biology of leukocyte mediated proteolysis. J Leukoc Biol. 1999 Feb;65(2):137-50.
20. Baydanoff S, Nicoloff G, Alexiev C. Age-related changes in antielastin antibodies in serum from normal and atherosclerotic subjects. Atherosclerosis. 1987 Feb;63(2-3):267-71.
21. Wrenn DS, Mecham RP. Immunology of elastin. Methods Enzymol. 1987;144:246-59.
22. Tzvetanov P, Hegde V, Al-Hashel JY, Atanasova M, Sohal AP, Rousseff RT. Abnormal levels of serum anti-elastin antibodies in patients with symptomatic carotid stenosis. Clin Neurol Neurosurg. 2014 Jan;116:9-12.
23. Senior RM, Griffin GL, Mecham RP, Wrenn DS, Prasad KU, Urry DW. Val-Gly-Val-Ala-Pro-Gly, a repeating peptide in elastin, is chemotactic for fibroblasts and monocytes. J Cell Biol. 1984 Sep;99(3):870-4.
24. Maurice P, Blaise S, Gayral S, Debelle L, Laffargue M, Hornebeck W et al. Elastin fragmentation and atherosclerosis progression: the elastokine concept. Trends Cardiovasc Med. 2013 Aug;23(6):211-21.
25. Nicoloff G, Christova P. Elastin degradation products among obese children with family history of arterial hypertension. Diabetologia Croatica. 2003;32(1):25-8.
26. Adeyemi E, Benedict S, Abdulle A. A comparison of plasma polymorphonuclear leucocyte elastase levels in obese and lean individuals. J Int Med Res. 1998;26:252-6.
27. Sivaprasad S, Chong NV, Bailey TA. Serum Elastin-Derived Peptides in Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3046-51.
28. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. The risk and natural course of age-related maculopathy: follow-upat 6 and a half years in the Rotterdam study. Arch Ophthalmol. 2003 Apr;121(4):519-26.
29. Keeley FW, Alatawi A. Response of aortic elastin synthesis and accumulation to developing hypertension and the inhibitory effect of colchicine on this response. Lab Invest. 1991 Apr;64(4):499-507.
30. Bonithon-Kopp C, Touboul PJ, Berr C, Magne C, Ducimetière P. Factors of carotid arterial enlargement in a popular aged 59 to 71 years. Stroke. 1996 Apr;27(4):654-60.
31. Bizeto L, Mazzolini AB, Ribeiro M, Stelmach R, Cukier A, Nunes MPT. Interrelationship between serum and sputum inflammatory mediators in chronic obstructive pulmonary disease. Braz J Med Biol Res. 2008 Mar;41(3):193-8.
32. Zureik M, Robert L, Courbon D, Touboul PJ, Bizbiz L, Ducimetière P. Serum elastase activity, serum elastase inhibitors, and occurrence of carotid atherosclerotic plaques: the Etude sur le Vieillissement Artèriel (EVA) study. Circulatiоn. 2002 Jun;105(2):2638-45.
33. Kakuta Y, Aoshiba K, Nagai A. C-reactive protein products generated by neutrophil elastase promote neutrophil apoptosis. Arch Med Res. 2006 May;37(4):456-60.
34. Ooyama T, Sakamato H. Elastase in the prevention of arterial aging and the treatment of atherosclerosis. Ciba Found Symp. 1995;192:307-17.
35. Tuzhilin DA, Dreiling DA. Cardiovascular lesions in pancreatitis. Am J Gastroenterol. 1975 May;63(5):381-8.

Поиск по сайту